This symposium is a science-focused seminar of medical professionals with experience in potential benefits/risks associated with the use of medical marijuana to treat a range of behaviors in Autism Spectrum Disorder (ASD). Dr. Rachel Levine, Secretary of Health for the Commonwealth of Pennsylvania, will present an update on the
Agenda:
7:45 AM - 8:30 AM, Registration & Continental Breakfast
8:30 AM, Welcome Remarks by
9:00 AM - 9:40 AM,
Overview of Pennsylvania Medical Marijuana Program
9:45 AM - 10:15 AM,
Summary of Preclinical and Clinical Trials (Observational and Clinical) for Autism
Overview of ASD Symptoms Targeted for Treatment
Current Pharmacologic Treatment Approaches to ASD, Risks and Benefits, Successes and Failures
10:15 AM - 10:30 AM, Break
10:30 AM - 11:00 AM,
Overview of Medicinal Cannabis and Its Impact Across Various Indications. Where is the Sector Heading from a Regulatory Perspective?
11:00 AM - 11:30 AM,
Experiences in Treating ASD Patients with Medical Cannabis
11:30 PM - 12:00 PM,
Medical Cannabis and ASD Plus Other Indications. Experiences in Practice (Dosing and Response). How/Where Do We Target Future Research Efforts?
12:00 PM - 12:30 PM, Lunch/Networking
12:30 PM - 1:00 PM,
Summary of Key Outcomes to CHOP Observational Trial. Current Utilization in ASD (CHOP Study) to include PK Information
1:00 PM - 1:30 PM,
Update on Current CBD and Autism Trial
1:30 PM - 2:30 PM, Panel Discussion {Lead by
Can Collaboration Help Us Transcend Regulatory and Research Challenges? Who's on First?
2:30 PM - 3:00 PM,
What is Australia Doing? Zelda-sponsored Phase I/II ASD Clinical Trial
3:00 PM - 3:15 PM, Closing Remarks by
3:15 PM - 3:30 PM, Break
Research Study Parent Session
3:30 PM, Welcome
3:35 PM - 4:05 PM, Overview of CHOP Study and Presentation of General Interim Results to include Disease Burden of Children with ASD, Dosing Variability, Dosing Patterns and Dose Related to Efficacy (Educational Component)
4:05 PM - 4:35 PM, Parent/Provider Panel Discussion
4:35 PM - 4:45 PM, Questions
4:45 PM - 5:00 PM, Closing Remarks
Medical professionals treating pediatric patients with ASD
Medical professionals who are involved in or have a strong interest in treating ASD with medical cannabis
Medical staff at medical marijuana dispensaries
Parents/caregivers who are enrolled in the current CHOP Medical Cannabis and Autism study
Parents/caregivers who have child diagnosed with ASD and are seeking additional information regarding treatment with medical cannabis
Describe the current medical marijuana program in Pennsylvania
Identify the proper forms of medical marijuana that a patient may purchase in Pennsylvania
Understand who is authorized to recommend medical marijuana in Pennsylvania
List the most common behavioral conditions in ASD patients which are treated with medical marijuana
Understand the current pharmacologic treatments in ASD
Explain the physiologic mechanisms in treating ASD with medical cannabis
Describe areas for future research
Explain preliminary results of the CHOP study
Understand the current utilization of medical marijuana in the ASD population
Identify research challenges and solutions
No childcare services are available onsite.
Press attendance requires prior written approval. Contact support@albrechtevents.com with inquiries.
Need a hotel room?
We have secured a block of rooms at